Loading...

NCN

NCN

NUCANA PLC

(NCNA)

2025 6-K

Financial Results Update

19 Mar '26

Management Change

6 Jan '26

Leadership Change

17 Dec '25

Clinical Data Announcement

10 Dec '25

Q3 2025 Results

13 Nov '25

Patent Announcement

5 Nov '25

Clinical Data Release

14 Oct '25

Nasdaq Compliance

5 Sep '25

Presentation Announcement

3 Sep '25

Q2 Financial Results

20 Aug '25

ADS Ratio Change

1 Aug '25

Warrant Cancellation

21 Jul '25

ADS Ratio Change

11 Jul '25

Nasdaq Delisting Notice

9 Jul '25

Sales Agreement Signed

30 Jun '25

Warrant Agreements Update

27 Jun '25

Nasdaq Compliance Alert

20 Jun '25

Management Changes

18 Jun '25

Annual Report Released

5 Jun '25

Financial Results Report

2 Jun '25

General Meeting Passed

23 Apr '25

Financial Results Update

20 Mar '25

General Meeting Notice

18 Mar '25

CFO Departure

10 Feb '25

Third Quarter Results

25 Nov '24

Clinical Data Release

12 Nov '24

Funding Update

30 Sep '24

New Patent Announcement

26 Sep '24

Data Presentation

16 Sep '24

Study Discontinued

29 Aug '24

Q2 Financial Results

15 Aug '24

Annual Meeting Summary

18 Jun '24

Q1 Financial Results

16 May '24

Annual Report Announcement

13 May '24

Compliance Regained

1 May '24

ADS Ratio Change

16 Apr '24

Cancer Research Presentation

9 Apr '24

ADS Ratio Change

27 Mar '24

Financial Results Update

20 Mar '24

External Links:

SEC

On December 10, 2025, NuCana plc announced at the ESMO Immuno-Oncology Congress the latest clinical results for its drug NUC-7738 combined with pembrolizumab for treating PD-1 inhibitor-resistant metastatic melanoma.

AI Assistant

NUCANA PLC

2025

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.